Expanded Accessibility for neffy® Epinephrine Nasal Spray
The recent inclusion of neffy® on Express Scripts commercial formularies marks a significant milestone in enhancing access for patients dealing with Type 1 allergic reactions. This introduction empowers caregivers and patients, offering a crucial alternative in emergency situations.
What is neffy®?
neffy® is a groundbreaking intranasal epinephrine product specifically designed for individuals experiencing Type I allergic reactions. These reactions can be triggered by various allergens, such as foods, medications, or insect stings, potentially leading to life-threatening anaphylactic episodes. By providing a needle-free alternative to traditional epinephrine injectors, neffy® represents a significant advancement in treatment options for both adults and children weighing 30 kg (66 lbs) and above.
Innovative Delivery Method
As the first FDA-approved epinephrine nasal spray, neffy® offers a modern solution that has not been available for over 35 years. Its user-friendly design streamlines the administration process, allowing for swift and confident responses during allergy emergencies. Easy to carry and quick to use, neffy® can be a lifesaver for those at risk.
Benefits of Including neffy® on Formularies
The addition of neffy® to Express Scripts' Commercial National Formularies significantly increases patient access, particularly for the millions of individuals with commercial insurance. Sal Grausso, Head of Market Access at ARS Pharmaceuticals, emphasized that this enhancement in accessibility not only showcases the product's urgency but also underlines its role in addressing unmet medical needs in the allergy community.
Quick Implementation
From its introduction to its inclusion on the formularies, the swift eight-week turnaround reflects ARS Pharmaceuticals' commitment to improving patient access. The company is dedicated to identifying and mitigating barriers that often hinder individuals from receiving the vital care they need in allergic emergencies.
ARS Pharmaceuticals’ Commitment to Patient Access
ARS Pharmaceuticals is actively working to expand the availability of neffy® beyond Express Scripts. Formulating partnerships with other payers ensures that more patients gain access to this critical device. The company also offers a range of programs tailored to assist patients and caregivers in overcoming coverage and affordability challenges associated with obtaining neffy®.
Understanding Type I Allergic Reactions
Type I allergic reactions can occur swiftly, necessitating immediate action with epinephrine, the only FDA-approved treatment. While epinephrine autoinjectors are effective, many patients express concerns regarding their use during emergencies due to factors like fear of needles or device complexity. Statistics reveal that millions experience such reactions, but less than half carry their epinephrine devices consistently. This highlights the imperative for a more accessible approach, which neffy® provides.
About ARS Pharmaceuticals, Inc.
Operating at the forefront of biopharmaceuticals, ARS Pharmaceuticals focuses on creating innovative solutions that empower individuals at risk of severe allergic reactions. The company champions the advancement of neffy® (trade name EURneffy in the EU), ensuring its vital role in emergency treatments for allergic reactions remains paramount.
Frequently Asked Questions
What is neffy® used for?
neffy® is an intranasal epinephrine product indicated for the emergency treatment of Type I allergic reactions, including anaphylaxis.
How does neffy® work?
neffy® delivers epinephrine through the nasal membrane, providing a quick response option for severe allergic reactions.
Who can use neffy®?
neffy® is suitable for adults and children weighing 30 kg or greater experiencing Type I allergic reactions.
How should neffy® be stored?
neffy® should be stored in a cool, dry place, with temperature exclusions of up to 122 degrees Fahrenheit, and remains viable for 30 months.
Where can I learn more about neffy®?
For more information on neffy®, including patient support programs, visit www.ars-pharma.com.
